The NeuroBank collects a variety of biospecimens from subjects being evaluated and treated for neurologic conditions at the UK's Albert B. Chandler Hospital and the Kentucky Neuroscience Institute. The PI of the overall protocol is Tritia Yamasaki, MD, PhD.
Nearly 100 million Americans are afflicted with neurologic diseases and the combined annual costs of treating neurologic conditions surpasses 800 billion dollars. The number of people afflicted by neurologic conditions continues to rise with the increase in our aging population, as many neurodegenerative conditions have a predilection for the elderly. While these numbers underscore the importance of discovering and developing new diagnostic and treatment options, efforts are hampered by inadequate understanding of the underlying etiology, mechanisms, and pathophysiology.
The NeuroBank aims to support neurologic researchers in better understanding the disease process by providing access to biospecimens in order to accelerate translational and innovative research with an ultimate goal of improving diagnosis and treatment options for patients with neurologic diseases and disorders.
Early collection efforts are focused on CSF, blood, and tissue. However, the protocol also allows for the collection of urine, saliva, and a buccal swab and collection will encompass these specimens as well. Blood and CSF may be taken, as either a leftover or as an extra research sample, up to four times a year and all samples will be linked to clinical data (although researchers will only receive fully deidentified data).